Zongtao Zhou

422 total citations
23 papers, 338 citations indexed

About

Zongtao Zhou is a scholar working on Molecular Biology, Epidemiology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Zongtao Zhou has authored 23 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 9 papers in Epidemiology and 9 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Zongtao Zhou's work include Peroxisome Proliferator-Activated Receptors (15 papers), Liver Disease Diagnosis and Treatment (9 papers) and Diabetes Treatment and Management (9 papers). Zongtao Zhou is often cited by papers focused on Peroxisome Proliferator-Activated Receptors (15 papers), Liver Disease Diagnosis and Treatment (9 papers) and Diabetes Treatment and Management (9 papers). Zongtao Zhou collaborates with scholars based in China. Zongtao Zhou's co-authors include Zheng Li, Luyong Zhang, Liming Deng, Lijun Hu, Qiang Ren, Yawen Xu, Yueming Chen, Xuekun Wang, Yuyi Li and Bing Liu and has published in prestigious journals such as Journal of Medicinal Chemistry, British Journal of Pharmacology and European Journal of Pharmacology.

In The Last Decade

Zongtao Zhou

21 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zongtao Zhou China 12 217 127 111 91 43 23 338
Yunfeng Li China 7 144 0.7× 55 0.4× 75 0.7× 107 1.2× 13 0.3× 15 377
Roxane Mansouri France 11 270 1.2× 73 0.6× 84 0.8× 62 0.7× 8 0.2× 13 445
Joo-Ho Lee South Korea 8 145 0.7× 76 0.6× 90 0.8× 68 0.7× 16 0.4× 20 316
Shoichi Kanda Japan 10 258 1.2× 175 1.4× 245 2.2× 105 1.2× 24 0.6× 16 602
Martin Perreault Canada 12 111 0.5× 97 0.8× 71 0.6× 37 0.4× 20 0.5× 21 374
Yangliang Ye China 11 149 0.7× 103 0.8× 55 0.5× 96 1.1× 7 0.2× 23 364
Akifumi Kogame Japan 9 186 0.9× 129 1.0× 39 0.4× 127 1.4× 6 0.1× 14 380
Akshyaya Rath India 7 152 0.7× 83 0.7× 191 1.7× 48 0.5× 76 1.8× 10 346
Susana Núñez United States 9 188 0.9× 41 0.3× 209 1.9× 56 0.6× 60 1.4× 17 481
Isabelle Duplan France 7 128 0.6× 52 0.4× 59 0.5× 87 1.0× 13 0.3× 9 293

Countries citing papers authored by Zongtao Zhou

Since Specialization
Citations

This map shows the geographic impact of Zongtao Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zongtao Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zongtao Zhou more than expected).

Fields of papers citing papers by Zongtao Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zongtao Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zongtao Zhou. The network helps show where Zongtao Zhou may publish in the future.

Co-authorship network of co-authors of Zongtao Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Zongtao Zhou. A scholar is included among the top collaborators of Zongtao Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zongtao Zhou. Zongtao Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Huang, Wanqiu, Liming Deng, Yun‐Li Zhao, et al.. (2024). Renal Protection of HWL‐088and ZLY‐032, Two Dual GPR40/PPARδ Agonists, in Adenine‐Induced Renal Fibrosis Model. Chemistry & Biodiversity. 22(2). e202401598–e202401598.
3.
Ren, Qiang, Ya Chen, Zongtao Zhou, et al.. (2023). Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease. Journal of Medicinal Chemistry. 66(9). 6082–6104. 13 indexed citations
4.
Wang, Huiwen, Jian Zhang, Xiaoxun Zhang, et al.. (2022). Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1868(12). 166556–166556. 13 indexed citations
5.
Zhou, Zongtao, et al.. (2022). Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold. Bioorganic & Medicinal Chemistry. 56. 116615–116615. 6 indexed citations
6.
Zhou, Zongtao, Qiang Ren, Liming Deng, et al.. (2021). Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. European Journal of Medicinal Chemistry. 229. 114061–114061. 12 indexed citations
7.
Li, Zheng, Qiang Ren, Zongtao Zhou, et al.. (2021). Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome. European Journal of Medicinal Chemistry. 225. 113807–113807. 11 indexed citations
8.
Wang, Bin, Zongtao Zhou, Xin Zhao, et al.. (2021). Discovery of a novel and orally active Farnesoid X receptor agonist for the protection of acetaminophen‐induced hepatotoxicity. Chemical Biology & Drug Design. 99(3). 483–495. 4 indexed citations
9.
Zhou, Zongtao, Liming Deng, Lijun Hu, et al.. (2020). Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis. European Journal of Pharmacology. 882. 173300–173300. 10 indexed citations
10.
Hu, Lijun, Qiang Ren, Liming Deng, et al.. (2020). Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist. European Journal of Medicinal Chemistry. 211. 113106–113106. 11 indexed citations
11.
Li, Zheng, Yawen Xu, Xuekun Wang, et al.. (2020). Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease. Bioorganic Chemistry. 99. 103803–103803. 12 indexed citations
12.
Zhou, Zongtao, et al.. (2020). ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis. Pharmacological Research. 159. 105035–105035. 15 indexed citations
13.
Li, Zheng, Chunxia Liu, Zongtao Zhou, et al.. (2020). A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice. Pharmacological Research. 153. 104679–104679. 17 indexed citations
14.
Ren, Qiang, Liming Deng, Zongtao Zhou, et al.. (2020). Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM. Bioorganic Chemistry. 101. 103963–103963. 11 indexed citations
15.
Hu, Lijun, Zongtao Zhou, Liming Deng, et al.. (2020). HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis. Journal of Pharmacy and Pharmacology. 72(11). 1564–1573. 7 indexed citations
16.
Li, Zheng, Lijun Hu, Xuekun Wang, et al.. (2019). Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents. Bioorganic Chemistry. 92. 103254–103254. 22 indexed citations
17.
Li, Zheng, Qiang Ren, Xuekun Wang, et al.. (2019). Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold. Bioorganic Chemistry. 92. 103209–103209. 15 indexed citations
18.
Li, Zheng, Zongtao Zhou, & Luyong Zhang. (2019). Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016–2019): a patent review. Expert Opinion on Therapeutic Patents. 30(1). 27–38. 48 indexed citations
19.
Li, Zheng, et al.. (2018). Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ. European Journal of Medicinal Chemistry. 159. 267–276. 35 indexed citations
20.
Li, Zheng, Yueming Chen, Zongtao Zhou, et al.. (2018). Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents. European Journal of Medicinal Chemistry. 164. 352–365. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yunfeng Li Breakdown of academic impact, for papers by Roxane Mansouri Breakdown of academic impact, for papers by Joo-Ho Lee Breakdown of academic impact, for papers by Shoichi Kanda Breakdown of academic impact, for papers by Martin Perreault Breakdown of academic impact, for papers by Yangliang Ye Breakdown of academic impact, for papers by Akifumi Kogame Breakdown of academic impact, for papers by Akshyaya Rath Breakdown of academic impact, for papers by Susana Núñez Breakdown of academic impact, for papers by Isabelle Duplan
Rankless by CCL
2026